Press Releases
March 22, 2021
Proceeds to Support Pivotal Program of AU-011 for the First Line Treatment of Choroidal Melanoma and Expansion of Virus-like Drug Conjugate (VDC) Platform in additional Ocular Oncology Indications and Solid Tumors Lead Investors Matrix Capital Management and Surveyor Capital (a Citadel company) are
January 5, 2021
CAMBRIDGE, MA –January 5th, 2021 – Aura Biosciences, a clinical-stage oncology company developing a novel class of drug conjugate therapies for multiple oncology indications, today announced the appointment of David Johnson to its Board of Directors. Mr.
Displaying 11 - 13 of 13